Flash Finance

Glenmark Pharmaceuticals LimitedGLENMARKCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹2,226.70
MCap ₹62,843 Cr · P/E 307.3
Glenmark Pharmaceuticals Limited — Stock analysis & AI research Glenmark Pharmaceuticals Limited — Multibagger AI analysis Glenmark Pharmaceuticals Limited — Seasonality — best & worst months Glenmark Pharmaceuticals Limited — Technical indicators & charts Glenmark Pharmaceuticals Limited — Technical setup — score, trend, support & resistance Glenmark Pharmaceuticals Limited — Triple Top pattern forming Glenmark Pharmaceuticals Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 High Profit Growth Stocks📋 GARP Stocks (PEG Below 1)📋 Low Debt Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹2,435 Cr
Sales · Jun 2026
+1.7% YoY
₹613 Cr
Operating Profit · Jun 2026
-15.8% YoY
25.2%
OPM % · Jun 2026
-17.1% YoY
₹736 Cr
Net Profit · Jun 2026
+122.8% YoY
₹26.07
EPS · Jun 2026
+122.8% YoY

📝 Glenmark Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Glenmark Pharmaceuticals Limited reported revenue of ₹2,435 crore for the quarter ended June 2026 (Q1 FY27), up 1.7% from ₹2,395 crore in the same quarter last year, and up 13.4% sequentially over the March 2026 quarter.

Net profit rose 122.8% year-on-year to ₹736 crore, from ₹330 crore. Earnings per share (EPS) came in at ₹26.07.

Operating profit stood at ₹613 crore — an operating margin (OPM) of 25.2%, compared with 30.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Glenmark Pharmaceuticals Limited posted revenue of ₹8,441 crore, a decline of 8.5% over FY25, with a net loss of ₹201 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹8,481 crore with a net profit of ₹205 crore.

Valuation snapshot

At the current price of ₹2,226.70, GLENMARK has a market capitalisation of ₹62,843 crore and a trailing P/E of about 307.3.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 11th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 46.65%, foreign institutional investors (FIIs) 20.35%, domestic institutional investors (DIIs) 19.28%, the government 0.04%, public shareholders 13.70% of Glenmark Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹62,843 Cr
Current Price ?
₹2,226.7
P/E ?
307.28above ind
Industry P/E ?
35.00
P/B ?
2.60
P/S ?
7.41
P/FCF ?
2,327.52
Enterprise Value ?
₹62,950 Cr
EV/EBITDA ?
65.37
PEG ?
N/A
Earnings Yield ?
1.1%
Dividend Yield ?
0.12%
Profitability & Returns
Sales (TTM) ?
₹8,481 Cr
OPM ?
11.4%
Profit after tax (TTM) ?
₹205 Cr
EPS (TTM) ?
₹7.25
ROCE ?
7.0%
ROE ?
0.8%
ROA ?
0.7%
Growth
Sales — latest qtr ?
₹2,435 Cr
PAT — latest qtr ?
₹736 Cr
YoY qtr sales growth ?
1.7%
YoY qtr profit growth ?
122.8%
Sales growth (3y) ?
1%
Sales growth (5y) ?
2%
Profit growth (3y) ?
0%
Profit growth (5y) ?
0%
Financial Health
Debt ?
₹107 Cr
Debt to Equity ?
0.00
Interest Coverage ?
10.7
Current Ratio ?
N/A
Ownership
Promoter holding ?
46.65%
Change in promoter holding ?
0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
-0.4%
Return 6 months ?
-1.0%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1,9392,1442,2331,3652,1482,3302,6362,2512,0102,3951,5392,3602,1472,435 +1.7% +13.4%
Operating Profit 218485443-184497631779494341728-17849632613 -15.8% +1816.4%
Other Income -42549542595,9335683129-9169286109-61115 +66.5% +289.2%
Interest 596258748315128131523221823 +50.4% +29.1%
Depreciation 4749505152535555565859596062 +8.1% +3.9%
Profit Before Tax -313392389-766,295618795559181401-906347-107866 +115.9% +909.4%
Net Profit -137272302-204,614454595414148330-739282-74736 +122.8% +1094.1%
EPS -4.879.6310.72-0.72163.5016.0821.0914.665.2411.70-26.1910.00-2.6226.07 +122.8% +1095.0%
OPM % 11.2% 22.6% 19.8% -13.5% 23.1% 27.1% 29.6% 21.9% 17.0% 30.4% -11.6% 21.0% 1.5% 25.2% -17.1% +1580.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹9,227 Cr ₹8,441 Cr ₹8,481 Cr -8.5%
Operating Profit ₹2,245 Cr ₹1,078 Cr ₹963 Cr -52.0%
OPM % 24.33% 12.77% 11.35% -47.5%
NPM % 17.45% -2.38% 2.41% -113.6%
Other Income ₹177 Cr ₹403 Cr ₹449 Cr +128.0%
Depreciation ₹219 Cr ₹236 Cr ₹240 Cr +7.5%
Interest ₹49 Cr ₹79 Cr ₹87 Cr +61.5%
EBIT ₹2,026 Cr ₹842 Cr ₹723 Cr -58.4%
PBT ₹2,154 Cr ₹-266 Cr ₹199 Cr -112.3%
Tax ₹310 Cr ₹-32 Cr ₹28 Cr -110.2%
Net Profit ₹1,611 Cr ₹-201 Cr ₹205 Cr -112.5%
EPS ₹57.07 ₹-7.11 ₹7.26 -112.5%
Material Cost ₹1,452 Cr ₹2,350 Cr ₹2,343 Cr +61.8%
Employee Cost ₹812 Cr ₹1,329 Cr ₹1,375 Cr +63.6%
Extraordinary Items — ₹-431 Cr ₹-978 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 28282828 +0.0%
Reserves 17,84922,94224,47624,122 -1.4%
Borrowings 3,221707830107 -87.1%
Other Liabilities 3,4873,7362,7005,228 +93.6%
Total Liabilities 24,58627,41428,03329,485 +5.2%
Fixed Assets 1,7461,7561,9792,120 +7.1%
CWIP 17219815567 -56.8%
Investments 10,33412,96515,19515,202 +0.0%
Other Assets 12,33412,49610,70512,096 +13.0%
Total Assets 24,58627,41428,03329,485 +5.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1,474-49558954 -90.8%
Cash from Investing Activity -4323,197-49057 +111.6%
Cash from Financing Activity -978-2,666-95-95 +0.0%
Net Cash Flow 6435316 +433.3%
Free Cash Flow 1,601-69024927 -89.2%
CFO/OP 128%30%52%6% -88.5%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 111115101143 +41.6%
Inventory Days 117130156153 -1.9%
Days Payable 225307242326 +34.7%
Cash Conversion Cycle 3-6215-30 -300.0%
Working Capital Days 29125592 +67.3%
ROCE % 11%10%10%7% -30.0%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 46.64%46.64%46.65%46.65% +0.0%
FIIs 20.62%20.73%19.20%20.35% +6.0%
DIIs 17.64%18.61%20.09%19.28% -4.0%
Government 0.04%0.04%0.04%0.04% +0.0%
Public 15.05%13.97%14.02%13.70% -2.3%
No. of Shareholders 1,90,2101,98,7892,01,5841,96,105 -2.7%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Glenmark Pharmaceuticals Limited's revenue in Q1 FY27?
Glenmark Pharmaceuticals Limited reported revenue of ₹2,435 crore for the quarter ended June 2026 (Q1 FY27), up 1.7% from ₹2,395 crore in the same quarter last year, and up 13.4% sequentially over the March 2026 quarter.
What was Glenmark Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit rose 122.8% year-on-year to ₹736 crore, from ₹330 crore. Earnings per share (EPS) came in at ₹26.07.
What is GLENMARK's market capitalisation and P/E ratio?
At the current price of ₹2,226.70, GLENMARK has a market capitalisation of ₹62,843 crore and a trailing P/E of about 307.3.
Who owns Glenmark Pharmaceuticals Limited? (shareholding pattern)
As of Mar 2026, promoters held 46.65%, foreign institutional investors (FIIs) 20.35%, domestic institutional investors (DIIs) 19.28%, the government 0.04%, public shareholders 13.70% of Glenmark Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI